MOSHE SHIKE, M.D.; JOAN E. HARRISON, M.D.; WILLIAM C. STURTRIDGE, M.D., Ph.D.; CHERK S. TAM, M.D., Ph.D.; PETER E. BOBECHKO, M.D.; GLENVILLE JONES, Ph.D.; TIMOTHY M. MURRAY, M.D.; KHURSHEED N. JEEJEEBHOY, M.B., B.S.; Ph.D.
We have prospectively investigated calcium and bone metabolism in 16 patients receiving total parenteral nutrition for periods ranging from 7 to 89 months. In 12 patients, bone biopsies at 6 to 73 months after the start of parenteral nutrition showed osteomalacia. Plasma 25-hydroxyvitamin D levels were normal in all patients. Seven persons developed hypercalcemia, and 10 had hypercalciuria with a negative calcium balance. Serum phosphorus was normal and plasma parathyroid hormone level, normal or decreased. Three patients with the severest form of the disease had vitamin D withdrawn from their solutions. Subsequently, urinary calcium decreased, and serum calcium became normal; two persons reverted to a positive calcium balance. Thus, patients receiving total parenteral nutrition may develop metabolic bone disease characterized by osteomalacia, hypercalcemia, hypercalciuria, and a negative calcium balance. This may be caused by both defective mineralization and increased bone resorption induced by vitamin D, its metabolites, or another unrecognized factor.
SHIKE M, HARRISON JE, STURTRIDGE WC, TAM CS, BOBECHKO PE, JONES G, et al. Metabolic Bone Disease in Patients Receiving Long-Term Total Parenteral Nutrition. Ann Intern Med. ;92:343–350. doi: 10.7326/0003-4819-92-3-343
Download citation file:
Published: Ann Intern Med. 1980;92(3):343-350.
Endocrine and Metabolism, Metabolic Bone Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use